On-treatment change in bone turnover markers predicts 2-year bone mineral density after sequential therapy following romosozumab: a real-world cohort study - Takeaways - MDSpire

On-treatment change in bone turnover markers predicts 2-year bone mineral density after sequential therapy following romosozumab: a real-world cohort study

  • By

  • Ryo Nakano

  • Ayumi Ichisawa

  • Kenya Saruta

  • Masakazu Kogawa

  • Akira Fukuda

  • June 17, 2026

  • 0 min

Share

  • 1

    Romosozumab significantly increases bone mineral density (BMD), but predicting long-term BMD gains after therapy is challenging.

  • 2

    On-treatment changes in procollagen type I N-terminal propeptide (ΔP1NP) and tartrate-resistant acid phosphatase 5b (ΔTRACP-5b) were analyzed.

  • 3

    A greater decline in ΔP1NP during romosozumab treatment predicted greater cumulative BMD gain at 24 months.

  • 4

    The optimal ΔP1NP cutoff for predicting a good response was identified as -40.3 μg/L, with stronger predictive value in treatment-naïve patients.

  • 5

    The study highlights the clinical utility of monitoring bone turnover markers during romosozumab treatment, necessitating further validation.

Original Source(s)

On-treatment change in bone turnover markers predicts 2-year bone mineral density after sequential therapy following romosozumab: a real-world cohort study

  • by Ryo Nakano, Ayumi Ichisawa, Kenya Saruta, Masakazu Kogawa, Akira Fukuda

  • June 17, 2026

Related Content

Bone mineral density and bone turnover in adolescent girls with anorexia nervosa: a 3-year retrospective cohort study

Thyroid hormones and thyroid hormone sensitivity indices correlate with volumetric bone mineral density and vertebral fracture risk among the osteoporotic population in northern China

Multimodal integration of neuroimaging, transcriptomics and single-cell analysis reveals molecular correlates linking osteoporosis to brain abnormalities